AR117712A1 - Nanopartículas filamentosas que tienen efecto adyuvante de vacuna - Google Patents

Nanopartículas filamentosas que tienen efecto adyuvante de vacuna

Info

Publication number
AR117712A1
AR117712A1 ARP190103707A ARP190103707A AR117712A1 AR 117712 A1 AR117712 A1 AR 117712A1 AR P190103707 A ARP190103707 A AR P190103707A AR P190103707 A ARP190103707 A AR P190103707A AR 117712 A1 AR117712 A1 AR 117712A1
Authority
AR
Argentina
Prior art keywords
nanoparticles
filament
quillaja
vaccine effect
adjuvant vaccine
Prior art date
Application number
ARP190103707A
Other languages
English (en)
Original Assignee
Croda Int Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Croda Int Plc filed Critical Croda Int Plc
Publication of AR117712A1 publication Critical patent/AR117712A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a nanopartículas filamentosas, es decir de tipo en hebra que comprenden esterol y un componente derivado de Quillaja saponaria Molina seleccionado entre quillaja ácido y quillaja saponina. Más particularmente, la presente se refiere al uso de dichas nanopartículas de tipo en hebra en vacunas y administración de drogas o sistemas de adsorción, métodos para su producción y sus usos, tal como para usar como un adyuvante de vacuna y en terapia de cáncer.
ARP190103707A 2018-12-18 2019-12-17 Nanopartículas filamentosas que tienen efecto adyuvante de vacuna AR117712A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18213540.0A EP3669890A1 (en) 2018-12-18 2018-12-18 Filamentous nanoparticles having vaccine adjuvant effect

Publications (1)

Publication Number Publication Date
AR117712A1 true AR117712A1 (es) 2021-08-25

Family

ID=65003112

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103707A AR117712A1 (es) 2018-12-18 2019-12-17 Nanopartículas filamentosas que tienen efecto adyuvante de vacuna

Country Status (12)

Country Link
US (1) US20230321227A1 (es)
EP (2) EP3669890A1 (es)
JP (1) JP2022514276A (es)
KR (1) KR20210105389A (es)
CN (1) CN113365657A (es)
AR (1) AR117712A1 (es)
AU (1) AU2019409474A1 (es)
BR (1) BR112021011609A2 (es)
CA (1) CA3123475A1 (es)
TW (1) TW202038905A (es)
WO (1) WO2020127115A1 (es)
ZA (1) ZA202103649B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112691188A (zh) * 2020-10-06 2021-04-23 江苏艾洛特医药研究院有限公司 一种纳米化肿瘤疫苗的制备方法
KR20230023348A (ko) 2021-08-10 2023-02-17 주식회사 엘지에너지솔루션 전극 조립체

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
US3803124A (en) 1968-04-12 1974-04-09 Farmaceutici It Soc Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives
GB1235022A (en) 1969-06-04 1971-06-09 Laeaeke Ag A new method for the production of cyclophosphamide
DE2124023C3 (de) 1970-05-27 1980-07-10 Richter Gedeon Vegyeszeti Gyar R.T., Budapest Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin oder von deren Sulfaten
US4020270A (en) 1974-05-02 1977-04-26 Societa' Farmaceutici Italia S.P.A. L-lyxohex-1-enopyranose derivative
GB1467383A (en) 1974-06-12 1977-03-16 Farmaceutici Italia Daunomycin analogues
US4307100A (en) 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
DE2845574A1 (de) 1978-10-19 1980-04-24 Deutsches Krebsforsch Durch heterocyclische ringe oder alkylreste substituierte analoga von ccnu und verfahren zu deren herstellung
EP0111058B1 (en) 1982-11-26 1987-11-04 Nippon Kayaku Kabushiki Kaisha Process for producing 4'-demethyl-epipodophyllotoxin-beta-d-ethylidene-glucoside and acyl-derivative thereof
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
IT1250692B (it) 1991-07-23 1995-04-21 Procedimento per la preparazione di demetilepipodofillotossina- beta-d-glucosidi.
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
GB9719426D0 (en) 1997-09-13 1997-11-12 Johnson Matthey Plc Novel process
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
RU2446822C2 (ru) * 2010-04-19 2012-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) Иммуностимулирующий комплекс, способ его получения и применение
AR082846A1 (es) 2011-07-07 2013-01-16 Consejo Nac Invest Cient Tec Una formulacion que promueve la polinizacion dirigida de abejas meliferas hacia cultivos de girasol
CA2850296C (en) 2011-10-03 2021-01-12 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
UY34506A (es) * 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
CN105169386B (zh) * 2015-07-29 2018-06-19 浙江大学 一种新型通用型基质疫苗佐剂及其制备方法和用途

Also Published As

Publication number Publication date
KR20210105389A (ko) 2021-08-26
TW202038905A (zh) 2020-11-01
EP3897713A1 (en) 2021-10-27
ZA202103649B (en) 2022-09-28
BR112021011609A2 (pt) 2021-08-31
WO2020127115A1 (en) 2020-06-25
AU2019409474A1 (en) 2021-06-10
EP3669890A1 (en) 2020-06-24
CN113365657A (zh) 2021-09-07
JP2022514276A (ja) 2022-02-10
CA3123475A1 (en) 2020-06-25
US20230321227A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
BR112018016755A2 (pt) vacina contra o vírus da zica
BR112019000598A2 (pt) rna para terapia de câncer
MX2018007627A (es) Vacuna contra el virus del zika.
AR095962A1 (es) Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
ECSP18087352A (es) Formulaciones de un inhibidor de lsd1
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
ECSP18001613A (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112017007841A2 (pt) sistemas e métodos para a síntese do óxido nítrico
BR112014027681B8 (pt) Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
CL2019003091A1 (es) Terapia de combinación.
CO6501190A2 (es) Vacuna de pcsk9
AR117712A1 (es) Nanopartículas filamentosas que tienen efecto adyuvante de vacuna
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112017015789A2 (pt) vacina de vírus da influenza suína bivalente
BR112017019358A2 (pt) combinações e formulações de dose fixa compreendendo etc1002 e ezetimiba e métodos de tratamento ou redução do risco de doença cardiovascular
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
BR112018002530A2 (pt) combinações e usos e tratamentos destas
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
AR116451A1 (es) Administración oral de análogos del péptido glp-1
BR112017013574A2 (pt) conjugados de aminoácido e peptídeo e usos dos mesmos